Last updated: 15 days ago
Moderna, Inc. Financial Report: Mixed Signals as of June 30, 2025
Explore Moderna's Q2 2025 financial report highlighting a net loss of $825M, cash decline, and deferred revenue growth. Investment recommendation: Hold.
Posts With Tag COVID-19 Vaccine
Showing 1 - 6 of 6 Posts
Last updated: 4 months ago
Moderna, Inc. Q1 2025 Financial Report: Insights & Future Predictions
Explore Moderna's Q1 2025 financial performance, revealing key sales, losses, and strategic recommendations for investors amid evolving market dynamics.
Last updated: 6 months ago
Moderna, Inc. 2024 Financial Report: Losses and Growth Potential Revealed
Explore Moderna, Inc.'s 2024 financial report highlighting $8.362B revenue, $3.607B loss, and R&D prospects. Investors advised to hold amid market challenges.
Last updated: 7 months ago
Moderna, Inc. 8-K Filing Report: Key Insights for Investors
Discover crucial details from Moderna's 8-K filing on January 13, 2025, highlighting significant corporate events and insights for investors. Ticker: MRNA.
Last updated: 8 months ago
BioNTech SE's $467M Royalty Settlement with Penn: Key Insights from Form 6-K
Explore BioNTech SE's financial report detailing a $467M royalty settlement with the University of Pennsylvania, including Pfizer's $170M reimbursement and key agreement terms.
Last updated: 8 months ago
BioNTech SE's $791.5M Settlement Report - Key Insights & Implications
Explore BioNTech SE's Form 6-K report detailing a $791.5M settlement with the NIH over COVID-19 vaccine royalties and new licensing terms effective January 2024.